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WADA Report on ATP positive Drug Tests 
 
On Friday 17th July 2004 at 1pm British Summer Time the World Anti Doping 
Agency, (WADA), released it’s report into the occurrence of seven positive urine 
samples of 19-norandrosterone1 administered by the Association of Tennis 
Professionals2, (ATP), amongst its members between August 2002 and May 
2003. In addition to these positive results there were also a further 36 samples 
that had what were described as elevated levels of nandrolone or its derivatives. 
These elevated levels are not enough for a player to be banned from competition 
but they are nevertheless sufficiently high to be of concern to the administrators 
of the sport and due to their elevated nature cannot be classified as negative. 
WADA, at the request of the ATP produced their report which related:3 
“On 8 August 2003 ATP formally requested that 
WADA perform an oversight review of ATP’s 
“investigation and administration relating to the seven 
player samples collected between August 2002 and 
May 2003 which were reported as analytically positive 
for 19-norandrosterone”. … WADA undertook to 
respect the confidentiality of the players involved. No 
names or other identifying information were provided 
to WADA when conducting this review”. 
 
                                            
1
 A derivative of nandrolone, which is an anabolic steroid, only available generally on prescription 
and administered via injection. 19-norandrostendione and 19-norandrostenedoil on the other 
hand are steroid precursors which may be purchased for oral use without prescription as 
nutritional supplements in health food stores and over the internet in many countries. (Young, p2) 
2
 The governing body of men’s tennis and the administrators of all men’s professional 
tournaments outside of the “Grand Slam” events of the Australian Open, the French Open, 
Wimbledon and the US Open 
3
 WADA, “WADA report on ATP cases”, July 2004, at p2 
The initiation of this report was prompted by the inconsistencies surrounding 
these failed and elevated tests. An earlier report into the failed tests had 
previously been commissioned by the ATP,4 which stated:5 
“These test results were extraordinary in three 
respects. First, this large number of positive and 
elevated tests in a short period is very unusual, 
particularly for tennis, which has never before had a 
pattern of tests involving nandrolone or its related 
substances. Second, all of the tests involved low 
levels of the metabolite, suggesting the source may 
have been a contaminated supplement. Third, and of 
particular importance, most of the samples had a 
common analytical fingerprint indicating that the same 
product had caused the positive and elevated tests”. 
 
Concern was expressed amongst the tennis community that there existed the 
possibility that these samples had suffered some form of contamination. Young 
explained:6 
“A study commissioned by the IOC and conducted at 
the Cologne laboratory concluded that supposedly 
clean supplements sold by companies that also sell 
steroid precursors are more likely to be contaminated 
than supplements from companies that do not sell 
steroid precursors. … Studies by the IOC 
Laboratories in Cologne and at UCLA have 
demonstrated that even the most miniscule amounts 
of contamination (several billionths of a gram in a 
tablet) can cause a positive test. Even product testing 
to the US pharmaceutical standard of 99.9% purity 
provides no protection since contamination as low as 
0.004% can cause a positive test”. 
 
                                            
4
 The report author was Richard Young, attorney at law and a partner in the firm of Holme 
Roberts and Owen LLP, specialising in anti-doping issues in sport. He is an experienced 
arbitrator for the Court of Arbitration for Sport. 
5
 Young R. “Investigation report regarding the detection of 19-Norandrosterone in the urine of 
numerous ATP players between August 2002 and May 2003” at p1 
6
 Young R. “Investigation report regarding the detection of 19-Norandrosterone in the urine of 
numerous ATP players between August 2002 and May 2003” at p3  
These particular factors are obviously a major concern and any erosion 
whatsoever of the principle of strict liability, (as was subsequently witnessed in 
these cases), would lead inevitably to the widespread use of a defence based on 
these factors. 
In the most prominent of the seven failed cases, Bohdan Ulihrach was 
sanctioned with a two year suspension by a disciplinary panel. However, in one 
of the other six cases, in his defence, one of the players, WADA report:7 
“included an allegation that the ATP had supplied the 
player, through one of its trainers, with a supplement, 
namely electrolyte tablets”. 
 
This allegation was sufficient to prompt the ATP to withdraw the electrolytes, 
under the suspicion that they may be a possible source of such contamination. 
The compelling similarities in the test results produced by these and other 
players was a factor that would cause real problems for the ATP. The report 
continues:8  
“The ATP learned early in the Inquiry, from Dr. Ayotte9 
at the Montreal laboratory, that not only were there 
seven positive cases, but another 36 analyses which 
indicated elevated levels of 19-Norandrosterone. Dr 
Ayotte had undertaken research into all of the 43 
cases and reached a conclusion that all must have 
been ‘caused by the same source’ because the 
analyses revealed a common analytical fingerprint 
in all samples”. (Emphasis added) 
 
From 1992-2002, the ATP had only one positive test for the substances in 
question and yet in an eight month period from August 2002 through to May 
                                            
7
 WADA, “WADA report on ATP cases”, July 2004, at p7, para 6 
8
 WADA, “WADA report on ATP cases”, July 2004, at p8, para 8 
9
 Dr. Christiane Ayotte, Director of the IOC’s laboratory 
2003, 43 such tests were identified as being either positive or elevated for those 
products. The Young report in attempting to reconcile these issues reported:10 
“Changes in the number and distribution of ATP tests 
were carefully considered. Although the ATP did more 
tests at more tournaments than in prior years, and 
more out of competition tests, these changes do not 
explain the dramatic difference in test results. Indeed, 
only one of the 43 positive or elevated samples came 
from an out of competition test. … The demographics 
of the players producing the 43 positive or elevated 
samples were studied samples with particular care to 
look for any apparent pattern. No pattern emerged. 
Rather, these 43 samples were produced by a 
remarkably diverse group of players at 17 
tournaments taking place at different times in different 
parts of the world. Specifically, the players whose 
samples produced these results came from more than 
a dozen different countries on several continents, with 
many different native languages, and different 
coaches and personal trainers”. 
 
The conclusion reached by Dr. Ayotte, and reported by Young was that:11 
“The unique analytical pattern of these ATP cases 
indicates that the players’ positive and elevated levels 
of 19-norandrosterone could have been caused by a 
common source. The low levels of 19-norandosterone 
detected are consistent with the oral administration of 
contaminated nutritional supplements”. 
 
Bohdan Ulirach’s original case, under authority of the Tennis Anti-Doping 
Program adjudication process was presented to a Tribunal of Independent 
arbitrators. Following a finding that Ulirach had committed a doping offence, the 
afore-mentioned sentence was imposed, (i.e. a two year suspension): Ulirach 
                                            
10
 Young R. “Investigation report regarding the detection of 19-Norandrosterone in the urine of 
numerous ATP players between August 2002 and May 2003” at p4  
11
 Ayotte Dr C., cited by Young R. “Investigation report regarding the detection of 19-
Norandrosterone in the urine of numerous ATP players between August 2002 and May 2003” at 
p4  
 
appealed to the Court of Arbitration for Sport.  However, following the submission 
of the details of the anomalies contained in these tests to the representatives of 
the players concerned, the proceedings were re-opened by the Tribunal Chair. 
The result of this re-examination of the issues presented were to have the effect 
of driving a coach and horses through the principle of strict liability and formed 
the basis of the argument which Greg Rusedski used to escape sanction for his 
failed test later in the year12. Young stated:13  
“After considering this new evidence, the independent 
Tribunal in the Ulirach case reversed its previous 
finding of a doping offense. Ulirach’s eligibility and 
ATP ranking points were reinstated. The Ulirach 
Tribunal’s analysis of the strict liability provision under 
ATP rules is particularly important. The Tennis rule, 
like the IOC rule, provides that athletes are absolutely 
responsible for the presence of any prohibited 
substance in their urine. This is certainly fair in the 
case of contaminated supplements because any 
player who chooses to continue taking supplements 
is, assuming a known risk of a positive test. The 
Ulirach Tribunal found, in the unique circumstances of 
that case, that the strict liability rule was trumped by 
the general doctrine of equitable estoppel. The 
Tribunal found that because the ATP trainers had 
violated the ATP’s own warnings and had given 
players supplements, the burden shifted to the ATP to 
establish that the supplement distributed by its 
trainers were not contaminated with 19-norsteroids. 
The ATP could not meet this burden and as a result 
the Tribunal dismissed the case”. 
 
                                            
12
 The Greg Rusedski case formed no part of this WADA review and is detailed at greater length 
in “Tennis – when strict liability is not too strict” [2004] I.S.L.R. Issue 3, 65 
13
 Young R. “Investigation report regarding the detection of 19-Norandrosterone in the urine of 
numerous ATP players between August 2002 and May 2003” at p8 
The CAS appeal was therefore withdrawn.  The Ulirach Tribunal were mindful of 
the perception that their decision would impact severely on the sacrosanct 
principle of strict liability and in attempting to pacify these fears concluded:14 
“This Tribunal decision should not be read as a 
qualification of the concept of strict liability as that 
notion has become understood under the CAS lex 
sportif. This situation is, in the experience of this 
Tribunal, and we suspect in the experience of the 
world of sport, a unique set of circumstances. These 
reasons should not be read as placing any sort of 
qualification on the strict liability principle because of 
an assertion by an athlete that the analytical results 
being challenged may have arisen because of a 
supplement made available to the athlete by 
competition sponsors or its sports federation. There 
has been extensive investigation by the ATP in this 
matter for which it should be commended for the 
integrity with which it conducted itself. To the ATP’s 
credit and with considerable courage it voluntarily 
undertook in the face of a very perplexing set of facts 
to investigate and ultimately implicate itself in the 
problem in which they and the players found 
themselves. The principles applied in this case are 
not to be read as a qualification or refinement of the 
principles of strict liability”. 
 
The importance of the principle of strict liability is illustrated by former Olympic 
champion and current Chair of London’s bid for the 2012 Olympics, Lord Coe, 
who in the wake of the Dwain Chambers decision15, opined:16 
“While the rule of strict liability – under which athletes 
have to be solely and legally responsible for what they 
consume – must remain supreme, one cannot help 
but feel queasy that, as he starts his two-year ban, 
Chambers was caught in the crossfire of a war that 
                                            
14
 Ulirach Tribunal report, cited in Young R. “Investigation report regarding the detection of 19-
Norandrosterone in the urine of numerous ATP players between August 2002 and May 2003” at 
p10 
15
 Chambers was found guilty of taking an illegal steroid and banned from athletics for a period of 
two years, despite his argument that it was unknown to him how the banned drug, (THG), had got 
into his system 
16
 Coe S., “We cannot move from strict liability rule”, Daily Telegraph, 25 February 2004 
was obviously a skirmish between the sport’s 
authorities and a dubious laboratory. However, we 
cannot, without binding reason and cause, move 
one millimetre from strict liability – if we do, the 
battle to save sport is lost”. (Emphasis added) 
 
Furthermore, commenting on this case and in particular on the sidelining of strict 
liability, Dr. Ayotte explained in a letter to Richard Young:17 
“I have come to accept my work in this field because I 
am entirely and morally satisfied with its outcome, 
globally and in each individual positive case. I feel 
differently here. This is a very unique situation. For 
the first time in my career I doubt that it is fair to apply 
the strict liability rule in these cases”. 
 
It is clear that it required very special circumstances to persuade the appropriate 
authorities to depart from this principle. However, this was the path that the ATP 
chose to take, opening themselves up to abuse of this humane concession in 
future cases and it must be questioned whether this was a wise path particularly 
when it is remembered that the ATP, although being the governing body of the 
men’s tour is in effect also the union of the players and therefore it may be 
argued that they have a conflict of interest in protecting the careers of any player 
found guilty of a doping offence. 
Following the exoneration of the players involved, further analysis determined 
that the electrolytes handed out by the ATP trainers could not be responsible for 
the positive and elevated test results. The WADA report states:18 
“Further information that has been made available to 
WADA during the carrying out of this inquiry reveals 
that there continue to be near-positive results with the 
same fingerprint. This only accentuates the fact 
                                            
17
 Ayotte Dr. C., “Investigation report regarding the detection of 19-Norandrosterone in the urine 
of numerous ATP players between August 2002 and May 2003”, Annex 4 
18
 WADA, “WADA report on ATP cases”, July 2004, at p13, para 19 
that it could not have been the electrolyte 
supplied by the ATP players during the period 
August 2002-May 2003 that led to the positive 
analytical results. If that is the case, and there 
seems to be no evidence to the contrary now, then 
the exonerations were clearly based on an incorrect 
factual finding. The facts as now known could not 
have supported the shifting of the onus of proof to the 
ATP nor could they support the application of the 
principle of estoppel. It is regrettable that the true 
picture and the full evidence were not available at the 
first hearings where the decisions were made”. 
(Emphasis added) 
 
With this in mind, the decision to exonerate the players appears to be 
dangerously flawed. The justification for the decisions to ignore the principle of 
strict liability was that the ATP could themselves, through their trainers have 
caused these test results. With this theory in tatters, and yet the ATP unwilling or 
unable to revisit the decisions, the authority and reputation of the governing body 
of men’s professional tennis has suffered a severe blow. WADA continue:19 
“Under the strict liability principle which is, and must 
be, the bedrock of any anti-doping program, it is not 
ATP’s responsibility to track the source of any 
elevated or positive result. It is for the player to prove 
how the substance gets into his/her body. 
Again, ATP, being a player association, 
understandably wants to assist its members in 
detecting such source. It is clear that now that the 
estoppel theory is no longer sustainable the ATP 
should be in a position to prosecute any positive case 
even if it has not been able to identify the source of 
contamination, if indeed there is a single source”. 
 
Where this saga leaves the principle of strict liability in general and more 
specifically doping control in tennis is open to question. The authority of the ATP, 
despite their protestations has been severely damaged and their departure from 
                                            
19
 WADA, “WADA report on ATP cases”, July 2004, at p19 at para 3(b) 
 
strict liability is a course of action that they appeared to be too willing to 
undertake. Whilst the WADA report may have criticised some of the dealings and 
reasoning of the ATP in their investigation of these cases,20 it did thankfully in no 
way cast doubt upon the integrity of the ATP. They did nevertheless heavily 
criticise the willingness of the organisation to readily accept the defence put 
forward by the players and the procedures under which the ATP pursued their 
enquiries:21   
“Principles of law must be based on facts. When the 
facts are incorrect, then the principles can be 
incorrectly applied. It is WADA’s considered view that 
this is one of those situations. 
There is no issue of lack of integrity in the ATP 
investigation, nor any question of bona fides in the 
way it was conducted, nor in the conclusions of the 
investigation. The ATP took considerable steps and 
incurred considerable expense to try to establish the 
source of the positive analytical results. The result, 
however, is that because the matters were dealt with 
so quickly, there was not one of the cases which went 
through a normal arbitration process, there was not 
one player whose evidence was heard on oath or 
tested upon cross-examination before a Tribunal, nor 
were any of the experts so heard. Under the 
circumstances, and in hindsight, that is regrettable”. 
 
Whilst the reasons for the apparently common test results remain a mystery, an 
adherence to the principle of strict liability must be maintained. The position we 
have at present is that any player, who is found to have a test result of the 
manner of these 43 tennis professionals, merely has to align his case with those 
and he will ultimately be exonerated, as was seen with Greg Rusedski. As was 
pointed out in the WADA report, only one player originally raised the possibility of 
                                            
20
 WADA, “WADA report on ATP cases”, July 2004, at pp10-12 
21
 WADA, “WADA report on ATP cases”, July 2004, at p14, paras 23-24 
the electrolytes administered by the ATP trainers as having actually caused their 
failed drugs test and only once it had proved successful did other players then 
embrace the defence. 
Clearly something inexplicable has happened in relation to drug testing in the 
world of men’s professional tennis and the ATP, to their credit, are pursuing an 
answer seemingly at great expense.22 However, as pointed out by WADA, this 
pursuit is probably not the most productive use of time or resources:23 
“The ATP has informed WADA that this fingerprint 
continues to be found in samples from male tennis 
players. It is WADA’s view and recommendation that 
the topic be the subject of immediate research, and 
WADA suggests that collected and retained samples 
be used as part of such research. 
The continuation by ATP through another 
Commission to hunt for a source might be endless, 
and may not be the wisest use of funds. The ATP 
might be wise to allow research of a scientific kind to 
occur, and to persuade its players to consent and co-
operate to such a project so that independent 
researchers might carry it out as soon as possible. 
WADA carefully considered the possibility of 
recommending participation in any further inquiry 
commission. In these circumstances, it is WADA’s 
view that such a commission, while well-meaning, will 
not have the power or jurisdiction to obtain evidence 
sufficient to locate the cause or causes. The expense 
and resource required for it would be better applied to 
research. 
 
Until the source of these common test results is uncovered, it is essential for the 
integrity of anti-doping control in sport that the ATP reaffirm their commitment to 
the principle of strict liability. If they fail to do this then the men’s professional 
tennis tour risks being thrown into complete disrepute. The only realistic and 
                                            
22
 Through investigation via a further commission 
23
 WADA, “WADA report on ATP cases”, July 2004, at p20, para 6 
enforceable alternative to strict liability would be to declare an amnesty on all 
drug abuse in sport, and therefore to legalise all performance enhancing 
substances. This is a route that the sporting world and indeed society at large is 
at present unwilling to countenance and therefore is an argument to be pursued 
at a later date. 
 
 
 
 
